IL17A and colitis: Notably, inhibition of IL-17A has been shown to worsen colitis in mouse models [13, 14] and blocking of IL-17A and IL-17RA with the monoclonal antibodies SEC and BRO, respectively, in patients with CD not only failed efficacy, but appeared to worsen disease activity [15, 16].